One2Treat is a fast-growing tech company that is transforming trial design and treatment assessments by capturing the full medical value of therapies in a more meaningful way.
Born out of an internal IDDI project and grown as a strategic life science investment by Bright Roads, One2Treat is rethinking traditional endpoints to help biotech and pharma sponsors align their development programs with what matters most: better outcomes for patients.
Solutions Built on Patient Voice
One2Treat creates software solutions that help biopharmaceutical companies rethink how clinical trials are designed and interpreted. Their approach spans software, statistical methodology, data aggregation, and stakeholder engagement to combine multiple meaningful dimensions into a single, unified assessment – enabling a more holistic view of treatment effect.
Innovative Trial Design
By applying validated mathematical methods and combining multiple clinically relevant outcomes into a single assessment of the Net Treatment Benefit, One2Treat enhances real-world relevance with fewer patients.
Strategic Decisions Across Clinical Development
One2Treat’s solutions help identify and weigh preferences from patients, clinicians, regulators, and sponsors, reinforcing patient centricity and aligning development with meaningful treatment impact.
Benefit-Risk Assessment
From dose selection to go/no-go decisions and health technology assessments (HTA), One2Treat provides a coherent framework that bridges clinical innovation with commercial strategy and supports drug approval consulting and associated marketing service planning.
Invested in Change
One2Treat represents Bright Roads’ commitment to life science investments that make a tangible difference for drug developers and patients.